{"PURPOSE": [0], "Trastuzumab": [1], "deruxtecan": [2], "(T-DXd)": [3], "is": [4], "a": [5, 300], "human": [6], "epidermal": [7], "growth": [8], "factor": [9], "2": [10], "(HER2)\u2013directed": [11], "antibody-drug": [12], "conjugate": [13], "approved": [14], "in": [15, 141, 240, 274], "HER2-expressing": [16, 31, 49, 278, 306], "breast": [17], "and": [18, 21, 93, 116, 166, 221, 265], "gastric": [19], "cancers": [20], "HER2-mutant": [22], "non\u2013small-cell": [23], "lung": [24, 249], "cancer.": [25], "Treatments": [26], "are": [27], "limited": [28], "for": [29, 48, 286, 303], "other": [30], "solid": [32, 307], "tumors.": [33, 308], "METHODS": [34], "This": [35], "open-label": [36], "phase": [37], "II": [38], "study": [39, 257], "evaluated": [40], "T-DXd": [41, 298], "(5.4": [42], "mg/kg": [43], "once": [44], "every": [45], "3": [46], "weeks)": [47], "(immunohistochemistry": [50], "[IHC]": [51], "3+/2+": [52], "by": [53], "local": [54], "or": [55, 60, 67], "central": [56, 181], "testing)": [57], "locally": [58], "advanced": [59], "metastatic": [61], "disease": [62, 250], "after": [63], "\u22651": [64], "systemic": [65], "treatment": [66, 104], "without": [68], "alternative": [69], "treatments.": [70], "The": [71, 118], "primary": [72, 99], "end": [73, 83], "point": [74], "was": [75, 121, 129, 147, 158, 170, 191, 201, 213, 225, 284], "investigator-assessed": [76], "confirmed": [77], "objective": [78], "response": [79], "rate": [80], "(ORR).": [81], "Secondary": [82], "points": [84], "included": [85], "safety,": [86], "duration": [87], "of": [88, 242, 297], "response,": [89], "progression-free": [90], "survival": [91, 95, 263], "(PFS),": [92], "overall": [94], "(OS).": [96], "RESULTS": [97], "At": [98], "analysis,": [100], "267": [101], "patients": [102, 179, 276, 304], "received": [103], "across": [105], "seven": [106], "tumor": [107], "cohorts:": [108], "endometrial,": [109], "cervical,": [110], "ovarian,": [111], "bladder,": [112], "biliary": [113], "tract,": [114], "pancreatic,": [115], "other.": [117], "median": [119, 145, 156, 168, 199, 211, 223], "follow-up": [120], "12.75": [122], "months.": [123], "In": [124, 178], "all": [125, 142], "patients,": [126], "the": [127, 144, 155, 167, 189, 198, 210, 222, 269, 287, 294], "ORR": [128, 190], "37.1%": [130], "(n": [131, 186], "=": [132, 187], "99;": [133], "[95%": [134], "CI,": [135, 151, 162, 174, 194, 205, 217, 229], "31.3": [136], "to": [137, 153, 164, 176, 196, 207, 219, 231], "43.2]),": [138], "with": [139, 180, 252, 268, 277, 305], "responses": [140], "cohorts;": [143], "DOR": [146, 200], "11.3": [148], "months": [149, 160, 172, 203, 215, 227], "(95%": [150, 161, 173, 193, 204, 216, 228], "9.6": [152, 206], "17.8);": [154], "PFS": [157, 212], "6.9": [159], "5.6": [163], "8.0);": [165], "OS": [169, 224], "13.4": [171], "11.9": [175, 214], "15.5).": [177], "HER2": [182], "IHC": [183, 288], "3+": [184, 289], "expression": [185], "75),": [188], "61.3%": [192], "49.4": [195], "72.4),": [197], "22.1": [202], "not": [208], "reached),": [209], "8.2": [218], "13.0),": [220], "21.1": [226], "15.3": [230], "29.6).": [232], "Grade": [233], "\u22653": [234], "drug-related": [235, 247], "adverse": [236], "events": [237], "were": [238], "observed": [239, 285], "40.8%": [241], "patients;": [243], "10.5%": [244], "experienced": [245], "adjudicated": [246], "interstitial": [248], "(ILD),": [251], "three": [253], "deaths.": [254], "CONCLUSION": [255], "Our": [256], "demonstrates": [258], "durable": [259], "clinical": [260], "benefit,": [261], "meaningful": [262], "outcomes,": [264], "safety": [266], "consistent": [267], "known": [270], "profile": [271], "(including": [272], "ILD)": [273], "pretreated": [275], "tumors": [279], "receiving": [280], "T-DXd.": [281], "Greatest": [282], "benefit": [283], "population.": [290], "These": [291], "data": [292], "support": [293], "potential": [295], "role": [296], "as": [299], "tumor-agnostic": [301], "therapy": [302]}